Nurix Therapeutics, Inc. 8K

Nurix Therapeutics reported positive updated Phase 1a/1b clinical results for its BTK degrader bexobrutideg in CLL/SLL, highlighting strong efficacy, durable responses, and a favorable safety profile that support advancement to broader Phase 3 development.

Nurix Therapeutics, Inc. announced updated Phase 1a/1b clinical data for its investigational oral BTK degrader bexobrutideg (NX-5948) in chronic lymphocytic leukemia/small lymphocytic lymphoma, showing high objective response rates, durable progression-free survival of about 22.1 months in heavily pretreated relapsed/refractory patients, promising activity in earlier-line cohorts (including BTKi-exposed BCL2i‑naïve and BTKi‑naïve or treatment‑naïve patients), and a favorable safety profile with no dose-limiting toxicities or treatment-related Grade 5 adverse events, with these results to be presented at the 2026 European Hematology Association Congress and supporting Nurix’s plans for a broad Phase 3 monotherapy program in collaboration with Roche.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

8K

Source Type

sec

Accession

0001549595-26-000034

Alert Tier

6